journal article·2010-06

Functionalization of chitosan/poly(lactic acid‐glycolic acid) sintered microsphere scaffolds via surface heparinization for bone tissue engineering

Tao Jiang, Yusuf Khan, Lakshmi S. Nair, Wafa I. Abdel‐Fattah, Cato T. Laurencin

Publisher page

Abstract

Abstract Scaffolds exhibiting biological recognition and specificity play an important role in tissue engineering and regenerative medicine. The bioactivity of scaffolds in turn influences, directs, or manipulates cellular responses. In this study, chitosan/poly(lactic acid‐co‐glycolic acid) (chitosan/PLAGA) sintered microsphere scaffolds were functionalized via heparin immobilization. Heparin was successfully immobilized on chitosan/PLAGA scaffolds with controllable loading efficiency. Mechanical testing showed that heparinization of chitosan/PLAGA scaffolds did not significantly alter the mechanical properties and porous structures. In addition, the heparinized chitosan/PLAGA scaffolds possessed a compressive modulus of 403.98 ± 19.53 MPa and a compressive strength of 9.83 ± 0.94 MPa, which are in the range of human trabecular bone. Furthermore, the heparinized chitosan/PLAGA scaffolds had an interconnected porous structure with a total pore volume of 30.93 ± 0.90% and a median pore size of 172.33 ± 5.89 μm. The effect of immobilized heparin on osteoblast‐like MC3T3‐E1 cell growth was investigated. MC3T3‐E1 cells proliferated three dimensionally throughout the porous structure of the scaffolds. Heparinized chitosan/PLAGA scaffolds with low heparin loading (1.7 μg/scaffold) were shown to be capable of stimulating MC3T3‐E1 cell proliferation by MTS assay and cell differentiation as evidenced by elevated osteocalcin expression when compared with nonheparinized chitosan/PLAGA scaffold and chitosan/PLAGA scaffold with high heparin loading (14.1 μg/scaffold). This study demonstrated the potential of functionalizing chitosan/PLAGA scaffolds via heparinization with improved cell functions for bone tissue engineering applications. © 2009 Wiley Periodicals, Inc. J Biomed Mater Res, 2010
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Bone Tissue Engineering Materials · Connective tissue disorders research · Periodontal Regeneration and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (46)

Show source-provided references
1. 10.1016/j.suc.2006.06.01610.1016/j.suc.2006.06.016 ↗
2. 10.1126/science.849352910.1126/science.8493529 ↗
3. 10.1002/jbm.a.3081710.1002/jbm.a.30817 ↗
4. 10.1586/17434440.3.1.2110.1586/17434440.3.1.21 ↗
5. 10.1016/j.biomaterials.2004.11.05010.1016/j.biomaterials.2004.11.050 ↗
6. 10.1016/S0142-9612(02)00374-510.1016/S0142-9612(02)00374-5 ↗
7. 10.1002/jbm.a.3061210.1002/jbm.a.30612 ↗
8. 10.1016/j.biomaterials.2006.04.03810.1016/j.biomaterials.2006.04.038 ↗
9. 10.1016/0142-9612(94)90093-010.1016/0142-9612(94)90093-0 ↗
10. 10.1002/jbm.127010.1002/jbm.1270 ↗
11. 10.1016/S0142-9612(96)00167-610.1016/S0142-9612(96)00167-6 ↗
12. 10.1016/j.biomaterials.2004.08.03210.1016/j.biomaterials.2004.08.032 ↗
13. 10.1096/fj.02-0564fje10.1096/fj.02-0564fje ↗
14. 10.1042/BA2005007510.1042/BA20050075 ↗
15. 10.1016/S0142-9612(01)00137-510.1016/S0142-9612(01)00137-5 ↗
16. 10.1002/jbm.1020110.1002/jbm.10201 ↗
17. 10.1302/0301-620X.86B8.1426710.1302/0301-620X.86B8.14267 ↗
18. 10.1002/jbm.a.3005110.1002/jbm.a.30051 ↗
19. 10.1016/j.biomaterials.2006.05.02510.1016/j.biomaterials.2006.05.025 ↗
20. 10.1016/0006-291X(89)92377-210.1016/0006-291X(89)92377-2 ↗
21. Heparin stimulates the collagen‐synthesis in mineralized cultures of the osteoblast‐like cell‐line, MC3T3‐E1
22. 10.1002/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-B10.1002/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-B ↗
23. 10.1002/jbm.1023810.1002/jbm.10238 ↗
24. 10.1016/j.actbio.2005.03.00210.1016/j.actbio.2005.03.002 ↗
25. Heparin modulates the binding of insulin‐like growth‐factor (IGF) binding protein‐5 to a membrane‐protein in osteoblastic cells10.1074/jbc.270.47.28289 ↗
26. 10.1016/S0006-291X(03)01500-610.1016/S0006-291X(03)01500-6 ↗
27. Barr TL · 1994
28. Canalis E · 2000
29. 10.1007/s00132-002-0308-y10.1007/s00132-002-0308-y ↗
30. Effects of glycosaminoglycans on cell proliferation of normal osteoblasts and human osteosarcoma cells depend on their type and fine chemical compositions
31. 10.1016/j.atherosclerosis.2004.10.03510.1016/j.atherosclerosis.2004.10.035 ↗
32. Differential effects of heparin and low molecular weight heparin on osteoblastogenesis and adipogenesis in vitro10.1160/TH04-03-0199 ↗
33. 10.1002/jcb.2000710.1002/jcb.20007 ↗
34. JiangT LaurencinCT.Transactions of the 31st Annual Meeting of the Society for Biomaterials. Pittsburgh Pennsylvania.2006. p407.
35. Alberts B · 1994
36. 10.1182/blood.V89.9.323610.1182/blood.V89.9.3236 ↗
37. Effects of heparin and low‐molecular‐weight heparins on bone mechanical properties in rats10.1160/TH04-02-0081 ↗
38. 10.1080/03009742.1998.1172076910.1080/03009742.1998.11720769 ↗
39. 10.1002/jcp.104128031710.1002/jcp.1041280317 ↗
40. 10.1002/jcp.104138012910.1002/jcp.1041380129 ↗
41. 10.1083/jcb.109.1.44110.1083/jcb.109.1.441 ↗
42. 10.1002/jcp.104159010810.1002/jcp.1041590108 ↗
43. 10.1016/0092-8674(91)90512-W10.1016/0092-8674(91)90512-W ↗
44. 10.1126/science.164648410.1126/science.1646484 ↗
45. 10.1074/jbc.M30093720010.1074/jbc.M300937200 ↗
46. 10.1002/(SICI)1097-4636(199901)44:1<63::AID-JBM7>3.0.CO;2-S10.1002/(SICI)1097-4636(199901)44:1<63::AID-JBM7>3.0.CO;2-S ↗